David Berry is a physician-scientist turned venture capitalist at Flagship Pioneering who has founded or co-founded over 20 companies including Moderna, Valo Health, and Seres Therapeutics, often serving as both investor and hands-on CEO rather than staying purely on the investing side. He operates as both an inventor and investor, creating new scientific concepts from scratch across multiple sectors from human therapeutics to agriculture, with a particular focus on applying AI and computation to rewrite the drug discovery process.

• A strong focus on the intersection of artificial intelligence and biology to accelerate drug discovery. This is most evident in the frequent discussion of Valo Health and the Opal Computational Platform, specifically how AI can create closed-loop drug design capabilities to make the development process faster and more predictable than traditional methods.
• Advocacy for systemic modernization in healthcare, particularly regarding clinical trials and supply chains. The tweets often highlight technologies like digital twins as a way to generate step-function changes that make trials less expensive and more predictable, rather than just making incremental improvements to existing models.
• Enthusiasm for specific, transformative therapeutic breakthroughs in areas like the microbiome, obesity, and oncology. This includes celebrating milestones such as Seres Therapeutics' success in the microbiome field or Freenome's work with liquid biopsy, showing a preference for science that offers entirely new treatment paradigms for patients.
• A critical view of the traditional scientific establishment and research dogma. Several posts question whether peer review enforces too much rigid thinking that hinders innovation, suggesting a desire for founders who are willing to challenge how research is traditionally funded, reviewed, and accepted.
• Attention to the broader impact of environmental factors on global health and economies. This includes commentary on the catastrophic loss of biodiversity and the need for immediate action on climate change, framing these not just as ecological issues but as systemic risks that overlap with biological stability and economic health.